信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

未开盘 01-02 16:00:00 EST

5.58

-0.20

-3.46%

盘后5.58

+0.000.00%

18:15 EST

最高5.82	最低5.52	成交量28.95万
今开5.79	昨收5.78	日振幅5.11%
总市值2.67亿	流通市值1.91亿	总股本4,788万
成交额162.09万	换手率0.85%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":5.58,"timestamp":1767387600000,"preClose":5.78,"halted":0,"volume":289540,"hourTrading":{"tag":"盘后","latestPrice":5.58,"preClose":5.58,"latestTime":"18:15 EST","volume":48813,"amount":272376.88,"timestamp":1767395755836},"delay":0,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"未开盘","change":-0.2,"latestTime":"01-02 16:00:00 EST","open":5.79,"high":5.8151,"low":5.52,"amount":1620860.1208499998,"amplitude":0.051055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767603600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.78,"dividendRate":0.032258,"preHourTrading":{"tag":"盘前","latestPrice":5.91,"preClose":5.78,"latestTime":"08:27 EST","volume":530,"amount":3132.59998,"timestamp":1767360467408},"postHourTrading":{"tag":"盘后","latestPrice":5.58,"preClose":5.58,"latestTime":"18:15 EST","volume":48813,"amount":272376.88,"timestamp":1767395755836},"volumeRatio":1.261522051904996,"impliedVol":0.6255,"impliedVolPercentile":0.416},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2601078362","title":"和黄医药(00013)启动现正进行中的索凡替尼联合卡瑞利珠单抗用于治疗初治胰腺导管腺癌研究的III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601078362","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601078362?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:09","pubTimestamp":1767571757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，公司今日宣布启动索凡替尼联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨用于一线治疗转移性胰腺导管腺癌患者的中国II/III期研究的III期部分。首名患者已于2025年12月30日接受首次给药治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","BK1587","BK1588","BK4134","BK1191","BK4588","III","BK4007","BK4585","00013","BK4531"],"gpt_icon":0},{"id":"2600037932","title":"诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037932","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600037932?lang=zh_cn&edition=full","pubTime":"2026-01-02 09:22","pubTimestamp":1767316966,"startTime":"0","endTime":"0","summary":"【诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组】诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601023607534023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4134","III","BK1161","BK1574","09969","688428"],"gpt_icon":0},{"id":"2595427799","title":"汇量科技(01860)因PAGAC III Munich Holding (Cayman)Limited行使换股权发行约4746万股换股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2595427799","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595427799?lang=zh_cn&edition=full","pubTime":"2025-12-30 19:03","pubTimestamp":1767092596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇量科技(01860)公布，于2025年12月23日，公司接获PAGAC III Munich Holding (Cayman) Limited就行使换股权所发出的转换通知，将可转换债券本金额3000万美元及累计未偿还利息3,917,504美元的债券按照换股价，即每股换股股份5.54港元进行转换。公司将根据该转换向PAGAC III Munich Holding (Cayman) Limited配发及发行 47,460,016股换股股份，该等换股股份在所有方面与公司其他所有现有已发行股份享有同等地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1613","III","BK1518","01860","BK1137","BK1590","BK1586","BK4134"],"gpt_icon":0},{"id":"2595878686","title":"智飞生物德谷门冬双胰岛素注射液完成III期临床试验，有效性及安全性与原研药相当","url":"https://stock-news.laohu8.com/highlight/detail?id=2595878686","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595878686?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:34","pubTimestamp":1767000854,"startTime":"0","endTime":"0","summary":"中访网数据 重庆智飞生物制品股份有限公司于近日发布公告，宣布其控股子公司重庆宸安生物制药有限公司研发的德谷门冬双胰岛素注射液已获得III期临床试验总结报告。该药品适应症为治疗成人2型糖尿病。根据多中心、随机、开放、平行对照的临床试验结果，本品在有效性和安全性上与原研药德谷门冬双胰岛素注射液(诺和佳)相当，符合相关指导原则的要求。目前，除原研药外，国内有1家企业的同类产品已获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251229/31899920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1064130708.USD","300122","BK0188","BK0196","LU2580892789.USD","BK0077","LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","BK0046","BK4134","BK0239","III","LU1328615791.USD"],"gpt_icon":0},{"id":"2594233091","title":"北京软件和信息服务业协会AIGC工作委员会启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233091","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233091?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:50","pubTimestamp":1766652629,"startTime":"0","endTime":"0","summary":"北京商报讯（记者程靓）12月25日，据北京软件和信息服务业协会消息，北京软件和信息服务业协会AIGC工作委员会（以下简称“AIGC工委会”）日前在北京软件和信息服务业协会第十一届会员代表大会第三次会议上正式揭牌启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512253601928918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601928918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","BK4134"],"gpt_icon":0},{"id":"2593478754","title":"前11个月，崂山区规上软件信息服务业营收规模突破126亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478754","media":"观海新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478754?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:52","pubTimestamp":1766566320,"startTime":"0","endTime":"0","summary":"产业链规上企业数量达到88家前11个月，崂山区规上软件信息服务业营收规模突破126亿元青岛日报社/观海新闻12月24日讯 23日下午，观海新闻记者从崂山区举行的“产业链上的崂山好品牌”现场媒体见面会上获悉，截至11月份，崂山区规模以上软件信息服务业营收规模突破126亿元，全市第一。目前，该区软件信息服务业规模以上企业数量已达88家。今年以来，崂山区工业软件优势不断增强。特色应用软件水平取得新突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-24/doc-inhcwxmm4456218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III"],"gpt_icon":0},{"id":"2593872105","title":"华硕GPU Tweak III新版发布：修复NVIDIA驱动问题、新增1%及0.1% Low帧","url":"https://stock-news.laohu8.com/highlight/detail?id=2593872105","media":"快科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593872105?lang=zh_cn&edition=full","pubTime":"2025-12-22 12:18","pubTimestamp":1766377086,"startTime":"0","endTime":"0","summary":"快科技12月22日消息，近日，华硕正式发布了其显卡调优与监控工具GPU Tweak III的v2.0.7.3最新稳定版，此次更新解决了此前版本与NVIDIA驱动的兼容性冲突，并新增了1%和0.1% Low帧统计。在12月初的时候，不少用户反馈在安装NVIDIA GeForce 591.44驱动后GPU Tweak III无法正常启动，华硕随后推出了测试版尝试修复，但部分系统的稳定性仍不理想。不过华硕在12月19日发布的v2.0.7.3正式版彻底解决了这一问题，此外新版本在OSD实时显示和日志记录中新增了1%和0.1% Low帧统计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8pI15Vzje5c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["III","BK4134"],"gpt_icon":0},{"id":"2593212811","title":"核药进展如潮涌！远大医药(00512)创新RDC药物TLX591-CDx国内III期达到主要临床终点，诊疗一体化布局蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593212811","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593212811?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:14","pubTimestamp":1766312060,"startTime":"0","endTime":"0","summary":"目前，远大医药已有六款创新RDC获批开展注册性临床研究，其中四款已进入III期临床阶段，公司已进入创新核药产品的收获期。尤为值得一提的是，公司自主研发的全球创新FAP靶点小分子RDC药物GPN01530近期获FDA批准在美国开展诊断实体瘤的I/II期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4134","III","RDC","00512"],"gpt_icon":0},{"id":"2593512143","title":"远大医药(00512)用于诊断前列腺癌的创新在研放射性核素偶联药物TLX591-CDx中国 III 期临床研究成功达到主要临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2593512143","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593512143?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:10","pubTimestamp":1766311834,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 公布，集团用于诊断前列腺癌的创新在研放射性核素偶联药物 TLX591-CDx 在中国进行的 III 期临床试验，近日取得了积极的顶线结果，并成功达到了主要临床终点。这表明 TLX591-CDx 的 PET 成像检测对临床决策具有重要影响，可优化疑似生化复发的前列腺癌患者的临床治疗策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","III","00512","BK4134"],"gpt_icon":0},{"id":"2592811181","title":"天坛生物旗下成都蓉生重组八因子新药启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2592811181","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592811181?lang=zh_cn&edition=full","pubTime":"2025-12-20 10:42","pubTimestamp":1766198535,"startTime":"0","endTime":"0","summary":"中访网数据  北京天坛生物制品股份有限公司今日公告，其下属企业成都蓉生药业有限责任公司研发的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”已于近日正式启动III期临床试验。该药品注册分类为治疗用生物制品，拟用于A型血友病患者的出血控制、预防及手术出血预防。根据公告，该产品研发累计投入已达9868.32万元。目前，国内市场尚无同类产品上市，国际市场主要有赛诺菲公司的Eloctate和Altuviiio两款产品。该药品后续仍需完成III期临床试验、提交上市申请并通过国家药监部门审评审批，方可实现上市销售。天坛生物提示，药品研发周期长且存在不确定性，投资者需注意相关风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251220/31879523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0168","BK0188","BK0185","BK0239","BK0010","600161","III","BK0082","BK4134","BK0028","BK0046"],"gpt_icon":0},{"id":"2592146209","title":"G-III服装集团盘中异动 下午盘大幅下挫5.00%报30.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592146209?lang=zh_cn&edition=full","pubTime":"2025-12-20 04:27","pubTimestamp":1766176076,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日04时27分，G-III服装集团股票出现异动，股价快速跳水5.00%。截至发稿，该股报30.01美元/股，成交量27.949万股，换手率0.66%，振幅4.75%。G-III服装集团股票所在的服装制造行业中，整体跌幅为1.21%。其相关个股中，文斯控股、兰亭集势、Xcel Brands, Inc涨幅较大，儿童之家、金铉集团、雷克兰医疗工业较为活跃，换手率分别为4.78%、3.71%、3.11%，振幅较大的相关个股有文斯控股、兰亭集势、金铉集团，振幅分别为14.49%、14.13%、13.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122004275697a080a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122004275697a080a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4202","III","GIII","BK4134"],"gpt_icon":0},{"id":"2592199939","title":"阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199939","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199939?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:03","pubTimestamp":1766138580,"startTime":"0","endTime":"0","summary":"本次试验目的是评估不适合或拒绝化疗的EGFRm阳性III期不可切除NSCLC患者在放疗前使用奥希替尼作为诱导治疗及在放疗后继续使用奥希替尼直至疾病进展的有效性。甲磺酸奥希替尼片为化学药物，适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU2462157665.USD","BK4588","III","LU2236285917.USD","LU0109394709.USD","BK4568","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","AZN","BK4134","BK4585","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2592134408","title":"港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592134408?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK4134","688428","BK1574","III","BK0239","BK1161"],"gpt_icon":0},{"id":"2592973845","title":"新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973845?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:45","pubTimestamp":1766043917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司的控股子公司石药集团巨石生物制药有限公司开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。有关详细数据将于后续学术会议及期刊上发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK0226","300765"],"gpt_icon":0},{"id":"2592902308","title":"III期ARTISTRY-2研究达主要终点，吉利德新型HIV二联疗法展现潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902308","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902308?lang=zh_cn&edition=full","pubTime":"2025-12-18 07:05","pubTimestamp":1766012717,"startTime":"0","endTime":"0","summary":"12月15日，吉利德宣布III期ARTISTRY-2研究取得积极顶线结果。吉利德计划将ARTISTRY研究的III期结果提交给监管机构，并将在未来的科学大会上公布详细数据。在ARTISTRY-2研究中，每日一次的单片复方方案BIC/LEN达到了主要成功标准，其疗效非劣于BIKTARVY。ARTISTRY-2的研究结果将与III期ARTISTRY-1研究的发现共同构成监管申报的基础。吉利德已于2025年11月公布了ARTISTRY-1的顶线结果，显示BIC/LEN组合耐受性良好，在疗效上非劣于多片式抗反转录病毒治疗方案。目前尚无治愈HIV或艾滋病的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","IE00BKVL7J92.USD","LU1674673428.USD","SG9999015978.USD","BK4583","BK4566","LU1066053197.SGD","SG9999015952.SGD","GILD","BK4532","LU2087621335.USD","LU1778281490.HKD","LU0114720955.EUR","III","LU0234570918.USD","BK4585","BK4578","LU1585245621.USD","LU1674673691.USD","BK4139","LU2089984988.USD","BK4550","IE00B19Z3581.USD","LU1571399168.USD","LU1839511570.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0289739699.SGD","LU0058720904.USD","IE0002270589.USD","BK4568","LU2324357040.USD","SG9999015945.SGD","IE00BSNM7G36.USD","SG9999015986.USD","LU0889565916.HKD","LU1066051498.USD","BK4134","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU0882574055.USD","BK4588","LU2468319806.SGD"],"gpt_icon":0},{"id":"2591869882","title":"来凯医药-B(02105)：LAE002 (AFURESERTIB)针对HR+/HER2-局部晚期或转移性乳腺癌的III期临床试验(AFFIRM-205)已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591869882","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591869882?lang=zh_cn&edition=full","pubTime":"2025-12-15 08:17","pubTimestamp":1765757864,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已完成LAE002联合氟维司群针对治疗HR+/HER2-局部晚期或转移性乳腺癌伴随 PIK3CA/AKT1/PTEN基因改变患者的III期临床试验AFFIRM-205入组。III 期临床试验AFFIRM-205为一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。集团与齐鲁制药有限公司已于 2025年11月12日签订独家许可协议。根据许可协议的条款及条件，齐鲁制药获得在中国地区进行LAE002的研究、开发及商业化的独家许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161","BK4225","BK4203","III","BK4134","HR"],"gpt_icon":0},{"id":"2591865967","title":"复星医药控股子公司酮洛芬贴剂获准开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591865967?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。　　该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1593","BK0196","BK4134","BK0060","BK0183","600196","BK0012","BK0175","BK0187","BK0188","BK1515","BK0028","02196","BK1191","BK0239","BK0096","III"],"gpt_icon":0},{"id":"2589352213","title":"中慧生物-B(02627)：冻干人用狂犬病疫苗(人二倍体细胞)的III期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2589352213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589352213?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:13","pubTimestamp":1765185186,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，集团近期启动集团冻干人用狂犬病疫苗的III期临床试验。公司于2024年10月完成该在研疫苗的I期临床试验。狂犬病是由一种狂犬病病毒引起的严重病毒性疾病，可能导致意识模糊和渐进性瘫痪等严重症状。利用人二倍体细胞研制的狂犬病疫苗为世卫组织推荐的“金标准”狂犬病疫苗，具有强大的安全性。公司的在研狂犬病疫苗在已完成的I期临床试验中显示出良好的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","BK4134","III","BK1161","159646"],"gpt_icon":0},{"id":"2589885635","title":"劲方医药-B(02595)：GFH375治疗转移性胰腺癌注册性临床试验在首家研究中心启动 为全球首个口服KRAS G12D抑制剂单药对照化疗III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2589885635","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589885635?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:16","pubTimestamp":1764893771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375治疗经治 KRAS G12D突变型转移性胰腺癌患者的注册性III期试验已在北京大学肿瘤医院启动。这项多中心、开放标签、随机对照的III期试验将在约40家中心开展，计划入组约320例既往接受至少一种标准系统性治疗的转移性胰腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK4134","BK1515","BK1574","III","159938","02595"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4107","BK4139","III","LU0985320562.USD","EMA","BK4588","06855","BK4081","BK1161","BK4585","BK4533","BK1574","ALL","LU1571399168.USD","LU1699723380.USD","AAPG","LU2355687059.USD","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0574},{"period":"1month","weight":-0.0124},{"period":"3month","weight":-0.0329},{"period":"6month","weight":0.092},{"period":"1year","weight":0.7169},{"period":"ytd","weight":-0.0346}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022197},{"month":2,"riseRate":0.529412,"avgChangeRate":0.012941},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}